Nazrin Ahmadova_No.1
Selected journal : Science
Stimulated protein degradation to promote mitochondrial function and neuronal survival

What is the main question of the paper?
Neurodegenerative and mitochondrial disorders are mainly caused by excessive protein accumulation and incorrect localization. The researchers try to generate the treatment by exploring the possibility to develop E3 ligase agonists that can be used to exploit the ubiquitination ability of this enzyme. While targeted protein degradation (TPD) has shown it efficacy in cancer and autoimmune diseases treatment, it is still unknown about the capability of this technique against conditions caused mainly by dysregulated proteins, such as cytochrome C oxidase (COX) deficiency syndrome and Friedreich’s ataxia. This study demonstrates a new approach, referred as stimulated protein degradation (SPD), as a promising solution for suspension of collective pathogenic factors and maintaining cellular stability.
How did the anthor address the question?
■Step1
Identification of small molecules that can displace BEX protein
CUL2^FEM1B normally helps maintain mitochondrial function by removing proteins that obstruct mitochondrial protein import. However, its activity is inhibited by brain-expressed X-linked (BEX) proteins, which prevents it from recognizing its substrates. A paired fluorescence polarization screening assay was established to distinguish compounds that disrupted the interaction between FEM1B and BEX3 from those that interfered with its recognition of FNIP1 substrate. This distinction was important because the goal was to remove the inhibitor without preventing the enzyme from recognizing its natural substrates. Eventually, they found BEX displacer 1 (BD1) and its cell-active analog – BD2 that allows activation of E3 ligase by selectively displacing its inhibitor rather than directly modifying its catalytic activity.
■Step2
Proteomics analysis demonstrated BD2-mediated BEX displacement
The disruption of inhibitory effect of BEX was examined in the presence of BD2. Researchers utilized 3xFLAG-tagged FEM1B in combination with BD2 and detected the associated proteins using mass spectrometry. The results from proteomic analyses established that BD2 removed all identifiable BEX proteins from FEM1B. Moreover, BD2 prompted the degradation of mitochondrial FNIP1 reporter, indicating that BD2 can stimulate CUL2^FEM1B pool that targets FNIP1 at translocase of the outer mitochondrial membrane (TOM complex) during reductive stress.
■Step3
Therapeutic potential of BD2 in disease models
Finally, the researchers investigated whether BD2 could improve disease-associated cellular phenotypes. They used cellular models of COX deficiency syndrome, in which depletion of cIV assembly factors impaired ETC activity. BD2 restored ETC activity, promoted the formation of assembled cIV, and improved cellular fitness. Additionally, BD2 increased neuronal marker expression, decreased neuronal death, and restored cIV subunit levels in iPSC-derived neurons. In the Friedreich’s ataxia model, BD2 restored mitochondrial protein import and reduced neuronal death caused by FXN depletion.
What is the strength of the paper?
The most important step of this research was the development of a new strategy, stimulated protein degradation (SPD), for treatment of complex diseases caused by dysregulated proteins. Unlike conventional TPD, which focuses on eliminating a single disease-associated protein, SPD activates E3 ligases to enable the simultaneous ubiquitination of multiple substrates. This mechanism is particularly advantageous for treating diseases driven by several pathological proteins. Furthermore, the researchers successfully linked this protein degradation mechanism to downstream biological outcomes, such as improved mitochondrial protein import, enhanced ETC activity, restored cIV assembly, and increased neuronal survival. The steps of understanding and validating the inhibitory disruption ability of BD2, helped to use this molecular mechanism in improving mitochondrial diseases, which suggests that SPD may have a broader therapeutic potential.
Comment
The most striking idea here is that the drug does not pick its targets — evolution did. By releasing an E3 ligase from its inhibitor, a single compound degrades a coherent set of native substrates, which could shift target optimization from single drivers to functionally linked groups.
Comment by Toshifumi Otsuki


